Finding the target after screening the phenotype.
Although most screening for new drug leads is being directed at known or emerging molecular targets, there has been a renaissance in screening based on changes in cell or organismal phenotypes. Phenotype-based screening is accompanied by the challenge of identifying the molecular target or targets bound by the drug leads and responsible for their pharmacological activity. A variety of technologies and approaches are being explored for target identification after phenotypic screening. Direct approaches employing affinity chromatography, expression cloning and protein microarrays analyze the compound bound to its target. Indirect approaches are based on comparison of the genome-wide activity profile of the compound with databases of the activity profiles of other compounds with known targets or activity profiles following specific genetic changes. This review will use case studies of target identification efforts and highlight the advantages and disadvantages of the various approaches to target identification after phenotypic screening.
Hart
Charles P
CP
Galileo Pharmaceuticals, Santa Clara, CA 95054, USA. chart@thresholdpharm.com
D000818:Animals; D002846:Chromatography, Affinity; D015195:Drug Design; D020869:Gene Expression Profiling / Q000379:methods; D015723:Gene Library; D016678:Genome; D006801:Humans; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D010641:Phenotype; D040081:Protein Array Analysis / Q000379:methods; D011506:Proteins / Q000737:chemistry* / Q000302:isolation & purification; D040901:Proteomics; D049490:Systems Biology / Q000379:methods
D004364:Pharmaceutical Preparations; D011506:Proteins